New price of osimertinib/osimertinib in 2024 released, latest consultation

Osimertinib (Osimertinib) is an oral targeted therapy drug, mainly used to treat EGFR (epidermal growth factor receptor) gene mutation-positive advanced non-small cell lung cancer (NSCLC). As a third-generation EGFR tyrosine kinase inhibitor, Osimertinib blocks the proliferation and growth of tumor cells by inhibiting the EGFR signaling pathway, thereby inhibiting tumor development and metastasis.

Osimertinib/Osimertinib’s original research drug has now been launched in the domestic market and has been successfully included in my country’s medical insurance system. This means that patients can purchase this drug directly in China, and its price is roughly in the range of three to four thousand yuan. However, for the specific selling price and medical insurance reimbursement details, it is recommended that patients go to the local hospital pharmacy for detailed consultation. If patients are looking for more affordable options, they can consider foreign generic drugs. Currently, Laos and Bangladesh are the main markets for generic drugs, and their prices are usually only around a few hundred yuan, which has a significant advantage over domestic prices. At the same time, the ingredients of these generic drugs are basically the same as those of the original drugs.

Osimertinib/Osimertinibis usually given as an oral tablet in a dose of 80 mg once a day. During treatment, doctors will regularly monitor the patient's disease status and drug tolerance and make dose adjustments as needed. Patients should pay close attention to their own conditions during medication and report any adverse reactions or discomfort symptoms to their doctors in a timely manner.

Osimertinib/OsimertinibCommon adverse reactions include rash, diarrhea, drowsiness, fatigue, cough, etc. Serious adverse reactions may include interstitial pneumonia, cardiovascular events, visual impairment, etc. Therefore, patients need to have regular follow-up visits during the medication period and carry out treatment and management according to the doctor's recommendations.

In general, Osimertinib/Osimertinib, as a targeted therapy, has a high therapeutic effect and less toxic side effects.EGFRgene mutation-positive late-stage NSCLC patients provide an effective treatment option, improving the patient's survival rate and quality of life.